1832 Asset Management
CASC

1832 Asset Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

1832 Asset Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-3
Closed – – 679
2014
Q3 		$0 Buy
+3
New +$46 ﹤0.01% 674

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

1832 Asset Management's CASC Position: Q4 2014 in Review

1832 Asset Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2014, closing a stake of 3 shares.

1832 Asset Management first reported a position in CASC in Q3 2014 and held it in 1 quarter. The position peaked at $0 in Q3 2014. 86 funds tracked by Wall St. Rank hold CASC as of Q4 2014.

  • 1832 Asset Management reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • 1832 Asset Management sold 3 Cascadian Therapeutics, Inc. shares in Q4 2014.
  • 1832 Asset Management first reported a position in Cascadian Therapeutics, Inc. in Q3 2014 and held it in 1 quarter.
  • 1832 Asset Management's Cascadian Therapeutics, Inc. position peaked at $0 in Q3 2014.
  • 86 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2014.

Based on 1832 Asset Management's 13F filing for Q4 2014, filed 12 Feb 2015.